 |
|
|
|
August 2006 Cover
|
|
Patients who receive a HAART regimen containing
efavirenz (Sustiva, Stocrin) are at no greater risk for
developing depression than patients who receive a
protease inhibitor (PI)-based regimen, according to
a 355-patient
study published in Clinical Infectious
Diseases. In this substudy of the randomized
ALIZE-ANRS 099 trial, French researchers found a
high rate of depressive disorder in patients on
treatment (30 patients). However, no difference
in incidence of depression was observed between
patients receiving efavirenz and patients receiving a
PI (8% vs. 7%,
P = .56) through 48 weeks of follow-up.
Even when the follow-up period was extended to
three years,
no difference between the two arms was noted. The
study (which was not funded by a pharmaceutical
company) backs a major AIDS Clinical Trials Group
substudy (A5097s, by Clifford
et al) that last year found no significant,
lasting impact of efavirenz on neuropsychological
performance.
Editor's Note: from www.thebodypro.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
